NCT05995275View on ClinicalTrials.gov

A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

351

Participants

Timeline

Start Date

August 15, 2023

Primary Completion Date

July 8, 2025

Study Completion Date

July 8, 2025

Conditions
SmallpoxMpox
Interventions
BIOLOGICAL

mRNA-1769

Sterile liquid for injection

OTHER

Placebo

0.9% sodium chloride injection (normal saline)

Trial Locations (12)

BD9 6RJ

Bradford Teaching Hospitals NHS Foundation Trust, Bradford

BS2 8DX

University Hospitals Bristol and Weston NHS Foundation Trust, Bristol

NN17 2UR

Lakeside Healthcare Research, Corby

LE1 5WW

University Hospitals of Leicester, Leicester

L7 8XP

Liverpool University Hospitals NHS Foundation Trust, Liverpool

E1 4DG

Barts Health NHS Trust, London

NW1 2PG

University College London Hospitals, London

NW3 2QG

Royal Free London NHS Foundation Trust, London

SW10 9NH

Chelsea and Westminster Hospital NHS Foundation Trust, London

M23 9QZ

Medicines Evaluation Unit, Manchester

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford

LL13 7YP

North Wales Clinical Research Facility Centre, Wrexham

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY

NCT05995275 - A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age | Biotech Hunter | Biotech Hunter